Peptides and polypeptides as modulators of the immune response: Thymopentin - An example with unknown mode of action

Pharmaceutica Acta Helvetiae

Volumn 73, Issue 6, 1999, Pages 265-273

  Gonser, S ^a   Weber, E ^a   Folkers, G ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Immunotherapy; Peptides; Polypeptides; Thymopentin; Thymopoietins

Indexed keywords

COLONY STIMULATING FACTOR; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; THYMOPENTIN; THYMOPOIETIN;

AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; DRUG EFFECT; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; PROTEIN PHOSPHORYLATION; REVIEW; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; PEPTIDES; THYMOPENTIN;

EID: 0032789864     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00005-9     Document Type: Review

References (82)

1. Afeltra A., Galeazzi M., Basso P., Pietrucci A., De Pita O., Ferri G.M., Porzio F., Bonomo L. Immune imbalance in the synovial fluid of rheumatoid arthritis patients: effects of intra-articular injection of thymopentin. J. Biol. Regul. Homeostatic Agents. 5:1991;71-75.
2. Aiuti F., Businco L., Fiorilli M., Galli E., Quinti I., Le Moli S., Seminara R., Goldstein G. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies. Birth Defects Orig. Artic. Ser. 19:1983;267-272.
3. Alsheimer M., Fecher E., Benavente R. Nuclear envelope remodelling during rat spermiogenesis: distribution and expression pattern of LAP2/thymopoietins. J. Cell Sci. 111:1998;2227-2234.
4. Audhya T., Schlesinger D.H., Goldstein G. Complete amino acid sequences of bovine thymopoietins I, II, and III: closely homologous polypeptides. Biochemistry. 20:1981;6195-6200.
5. Audhya T., Heavner G.A., Kroon D.J., Goldstein G. Cooperativity of thymopoietin 32-36 (the active site) and thymopoietin 38-45 in receptor binding. Regul. Pept. 9:1984;155-164.
6. Balkwill F.R. Tumour necrosis factor and cancer. Prog. Growth Factor Res. 4:1992;121-137.
7. Basch R.S., Goldstein G. Induction of T cell differentiation in vitro by thymin, a purified polypeptide hormone of the thymus. Proc. Natl. Acad. Sci. U.S.A. 71:1974;1474-1478.
8. Beutler B., Cerami A. Cachectin/tumor necrosis factor: an endogenous mediator of shock and inflammation. Immunol. Res. 5:1986;281-293.
9. Botturi M., Panzarasa R., Agostara B., Armaroli L., Belli M., Barone D., Boccone F., Busutti L., Catalano E., Ciambellotti E.et al. Effects of the immunomodulation in antineoplastic radiation therapy. Controlled multicenter clinical trial. Radiol. Med. (Torino). 86:1993;327-335.
10. Brumeanu T.D., Casares S., Bot A., Bot S., Bona C.A. Immunogenicity of a contiguous T-B synthetic epitope of the A/PR/8/34 influenza virus. J. Virol. 71:1997;5473-5480.
11. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 80:1997;1198-1220.
12. Cantrell M.A., Anderson D., Cerretti D.P., Price V., McKereghan K., Tushinski R.J., Mochizuki D.Y., Larsen A., Grabstein K., Cosman D. Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. U.S.A. 82:1985;6250-6254.
13. Conant M.A., Calabrese L.H., Thompson S.E., Poiesz B.J., Rasheed S., Hirsch R.L., Meyerson L.A., Kremer A.B., Wang C.C., Goldstein G. Maintenance of CD4+ cells by thymopentin in asymptomatic HIV-infected subjects: results of a double-blind, placebo-controlled study. AIDS. 6:1992;1335-1339.
14. De Graw J.I., Almquist R.G., Hiebert C.K., Colwell W.T., Crase J., Hayano T., Judd A.K., Dousman L., Smith R.L., Waud W.R., Uchida I. Stabilized analogs of thymopentin: 1. 4,5-Ketomethylene pseudopeptides. J. Med. Chem. 40:1997;2386-2397.
15. Djeu J.Y., Liu J.H., Wei S., Rui H., Pearson C.A., Leonard W.J., Blanchard D.K. Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2. J. Immunol. 150:1993;960-970.
16. Duchateau J., Servais G., Cooman R., Collet H., Bolla K. In vitro influence of thymopentin on proliferative responses and phytohemagglutinin-induced interleukin 2 production in normal human lymphocyte cultures. Surv. Immunol. Res. 4(Suppl. 1):1985;116-124.
17. Espinoza-Delgado I., Bosco M.C., Musso T., Gusella G.L., Longo D.L., Varesio L. Interleukin-2 and human monocyte activation. J. Leukocyte Biol. 57:1995;13-19.
18. Figlin R.A. Renal cell carcinoma: management of advanced disease. J. Urol. 161:1999;381-386.
19. Fiorilli M., Sirianni M.C., Pandolfi F., Quinti I., Tosti U., Aiuti F., Goldstein G. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency. Clin. Exp. Immunol. 45:1981;344-351.
20. Fiorilli M., Sirianni M.C., Sorrentino V., Testi R., Aiuti F. In vitro enhancement of bone marrow natural killer cells after incubation with thymopoietin 32-36 (TP-5). Thymus. 5:1983;375-382.
21. Foisner R., Gerace L. Integral membrane proteins of the nuclear envelope interact with lamins and chromosomes, and binding is modulated by mitotic phosphorylation. Cell. 73:1993;1267-1279.
22. Friedmann N. Thymopentin: safety overview. Surv. Immunol. Res. 4(Suppl. 1):1985;139-148.
23. Frumkin L.R. Role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of patients with HIV infection. Curr. Opin. Hematol. 4:1997;200-206.
24. Furukawa K., Glass C., Kondo T. Characterization of the chromatin binding activity of lamina-associated polypeptide (LAP) 2. Biochem. Biophys. Res. Commun. 238:1997;240-246.
25. Gallin J.I., Farber J.M., Holland S.M., Nutman T.B. Interferon-gamma in the management of infectious diseases. Ann. Intern. Med. 123:1995;216-224.
26. Ganser A., Karthaus M. Clinical use of hematopoietic growth factors. Curr. Opin. Oncol. 8:1996;265-269.
27. Goldstein G. Isolation of bovine thymin: a polypeptide hormone of the thymus. Nature. 247:1974;11-14.
28. Goldstein G., Scheid M.P., Boyse E.A., Schlesinger D.H., Van Wauwe J. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science. 204:1979;1309-1310.
29. Gonalons E., Barrachina M., Garcia-Sanz J.A., Celada A. Translational control of MHC class II I-A molecules by IFN-gamma. J. Immunol. 161:1998;1837-1843.
30. Gonser S., Crompton N.E.A., Weber P.J.A., Beck-Sickinger A.G., Folkers G. TP5 triggers signal transduction involving mitogen activated protein kinases in monocytes. J. Recept. Signal Transduction Res. 19:1999;155-166.
31. Gray P.W., Leung D.W., Pennica D., Yelverton E., Najarian R., Simonsen C.C., Derynck R., Sherwood P.J., Wallace D.M., Berger S.L., Levinson A.D., Goeddel D.V. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature. 295:1982;503-508.
32. Harris C.A., Andryuk P.J., Cline S., Chan H.K., Natarajan A., Siekierka J.J., Goldstein G. Three distinct human thymopoietins are derived from alternatively spliced mRNAs. Proc. Natl. Acad. Sci. U.S.A. 91:1994;6283-6287.
33. Harris C.A., Andryuk P.J., Cline S.W., Mathew S., Siekierka J.J., Goldstein G. Structure and mapping of the human thymopoietin (TMPO) gene and relationship of human TMPO beta to rat lamin-associated polypeptide 2. Genomics. 28:1995;198-205.
34. Heavner G.A., Audhya T., Kroon D., Goldstein G. Structural requirements for the biological activity of thymopentin analogs. Arch. Biochem. Biophys. 242:1985;248-255.
35. Hershfield M.S. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin. Hematol. 35:1998;291-298.
36. Hoelzer D., Seipelt G. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of myeloid leukemia. Curr. Opin. Hematol. 2:1995;196-203.
37. Hong R. The DiGeorge anomaly (CATCH 22, DiGeorge/velocardiofacial syndrome). Semin. Hematol. 35:1998;282-290.
38. Kagan W.A., O'Neill G.J., Incefy G.S., Goldstein G., Good R.A. Induction of human granulocyte differentiation in vitro by ubiquitin and thymopoietin. Blood. 50:1977;275-288.
39. Kavanaugh A.F. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum. Dis. Clin. North. Am. 24:1998;593-614.
40. Kingston A.E., Bergsteinsdottir K., Jessen K.R., Van der Meide P.H., Colston M.J., Mirsky R. Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-gamma pretreatment: synergistic effects of interferon-gamma and tumor necrosis factor on MHC class II induction. Eur. J. Immunol. 19:1989;177-183.
41. Kisfaludy L., Nyeki O., Schon I., Denes L., Ember J., Szporny L., Hajos G., Szende B. Immuno-regulating peptides: I. Synthesis and structure-activity relationship of thymopentin analogs. Hoppe-Seyler's Z. Physiol. Chem. 364:1983;933-940.
42. Krebs S., Rognan D. From peptides to peptidomimetics: design of non-peptide ligands for major histocompatibility proteins. Pharm. Acta Helv. 73:1998;173-181.
43. Lazzarin A., Barcellini W., Uberti, Foppa C., Borghi M.O., Franzetti R., Cinque P., Moroni M. Experiences with immunomodulant agents in HIV infections. Acta Haematol. 78:1987;84-90.
44. Lejeune F.J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 10:1998;573-580.
45. Lloyd A. HIV infection and AIDS. P.N.G. Med. J. 39:1996;174-180.
46. Mantovani G., Coiana A., Massidda A., Locci F., Loy M., Piludu G., Piras M.C., Maccio A., Del Giacco G.S. Peripheral blood lymphocyte response to recombinant and non-recombinant interleukin 2 in previously treated patients with Hodgkin's disease, long-time off-therapy. Eur. J. Haematol. 38:1987;179-186.
47. Marley G.M., Doyle L.A., Ordonez J.V., Sisk A., Hussain A., Yen R.W. Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines. Cancer Res. 49:1989;6232-6236.
48. Martin M., Schwinzer R., Schellekens H., Resch K. Glomerular mesangial cells in local inflammation. Induction of the expression of MHC class II antigens by IFN-gamma. J. Immunol. 142:1989;1887-1894.
49. Murray H.W. Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med. 22:1996;456-461.
50. Neumunaitis J. A comparative review of colony-stimulating factors. Drugs. 54:1997;709-729.
51. Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., Kohr W.J., Aggarwal B.B., Goeddel D.V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 312:1984;724-729.
52. Pericle F., Liu J.H., Diaz J.I., Blanchard D.K., Wei S., Forni G., Djeu J.Y. Interleukin-2 prevention of apoptosis in human neutrophils. Eur. J. Immunol. 24:1994;440-444.
53. Philip R., Epstein L.B. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature. 323:1986;86-89.
54. Quesada J.R., Reuben J., Manning J.T., Hersh E.M., Gutterman J.U. Alpha interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med. 310:1984;15-18.
55. Rammensee H.-G., Friede T., Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:1995;178-228.
56. Rinderknecht E., O'Connor B.H., Rodriguez H. Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation. J. Biol. Chem. 259:1984;6790-6797.
57. Santoli D., Clark S.C., Kreider B.L., Maslin P.A., Rovera G. Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J. Immunol. 141:1988;519-526.
58. Schlesinger D.H., Goldstein G. The amino acid sequence of thymopoietin II. Cell. 5:1975;361-365.
59. Scuccimarri R., Rodd C. Thyroid abnormalities as a feature of DiGeorge syndrome: a patient report and review of the literature. J. Pediatr. Endocrinol. Metab. 11:1998;273-276.
60. Serrate S.A., Schulof R.S., Leondaridis L., Goldstein A.L., Sztein M.B. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J. Immunol. 139:1987;2338-2343.
61. Shapira M., Jibson M., Muller G., Arnon R. Immunity and protection against influenza virus by synthetic peptide corresponding to antigenic sites of hemagglutinin. Proc. Natl. Acad. Sci. U.S.A. 81:1984;2461-2465.
62. Singh V.K., Biswas S., Mathur K.B., Haq W., Garg S.K., Agarwal S.S. Thymopentin and splenopentin as immunomodulators. Immunol. Res. 17:1998;345-368.
63. Skoskiewicz M.J., Colvin R.B., Schneeberger E.E., Russell P.S. Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. J. Exp. Med. 162:1985;1645-1664.
64. Smith K.A. Interleukin 2. Annu. Rev. Immunol. 2:1984;319-333.
65. Stemme S., Fager G., Hansson G.K. MHC class II antigen expression in human vascular smooth muscle cells is induced by interferon-gamma and modulated by tumour necrosis factor and lymphotoxin. Immunology. 69:1990;243-249.
66. Sugarman B.J., Lewis G.D., Eessalu T.E., Aggarwal B.B., Shepard H.M. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res. 47:1987;780-786.
67. Sundal E. Thymopentin in cancer. Curr. Ther. Res. 51:1992;906-924.
68. Sundal E., Bertelletti D. Management of viral infections with thymopentin. Arzneimittelforschung. 44:1994;866-871.
69. Sunshine G.H., Basch R.S., Coffey R.G., Cohen K.W., Goldstein G., Hadden J.W. Thymopoietin enhances the allogenic response and cyclic GMP levels of mouse peripheral, thymus-derived lymphocytes. J. Immunol. 120:1978;1594-1599.
70. Swain S.L. Lymphokines and the immune response: the central role of interleukin-2. Curr. Opin. Immunol. 3:1991;304-310.
71. Takagi S., Minakuchi J., Okawa H., Yata J. Phenotypical and functional heterogeneity of the large granular lymphocytes increased after various treatments in a patient with combined immunodeficiency. J. Clin. Immunol. 9:1989;39-47.
72. Theodor L., Shoham J., Berger R., Gokkel E., Trachtenbrot L., Simon A.J., Brok-Simon F., Nir U., Ilan E., Zevin-Sonkin D., Friedman E., Rechavi G. Ubiquitous expression of a cloned murine thymopoietin cDNA. Acta Haematol. 97:1997;153-163.
73. Tischio J.P., Patrick J.R., Weintraub H.S., Chasin M., Goldstein G. Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma. Int. J. Pept. Protein Res. 14:1979;479-484.
74. Tovo P.A., De Martino M., Rossi P., Cavagni G., Masi M., Bardare M. The use of thymopentin in the prevention of recurrent infections of the respiratory system. Multicentre study. Minerva Pediatr. 45:1993;505-510.
75. Tracey K.J., Wie H., Manogue K.R., Fong Y., Hesse D.G., Nguyen H.T., Kuo G.C., Beutler B., Cotran R.S., Cerami A.et al. Cachetin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 167:1988;1211-1227.
76. Trinchieri G., Matsumoto-Kobayashi M., Clark S.C., Seehra J., London L., Perussia B. Response of resting human peripheral blood NK cells to IL-2. J. Exp. Med. 160:1984;1147-1169.
77. Veys E.M., Hermanns P., Goldstein G., Kung P., Schindler J., Van Wauwe J. Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis. Influence of immunomodulating agents. Int. J. Immunopharmacol. 3:1981;313-319.
78. Wiley D.C., Wilson I.A., Skehel J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 289:1981;373-378.
79. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv. Immunol. 56:1994;389-466.
80. Winchester R., Gregersen P.K., Merryman P., Dwyer E., Lee S. Hypotheses on the molecular basis of susceptibility to rheumatoid arthritis. Scand. J. Rheumatol. 76:1988;9-16.
81. Wong G.G., Witek J.S., Temple P.A., Wilkens K.M., Leary A.C., Luxenberg D.P., Jones S.S., Brown E.L., Kay R.M., Orr E.C., Shoemaker C., Golde D.W., Kaufman R.J., Hewrick R.M., Wang E.A., Clark S.C. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science. 228:1985;810-815.
82. Yang L., Tinglu G., Gerace L. Lamin-binding fragment of LAP2 inhibits increase in nuclear volume during the cell cycle and progression into S phase. J. Cell Biol. 139:1997;1077-1087.